| Bioactivity | SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-1 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 3.48 μM[1]. | ||||||||||||
| Target | SEC | ||||||||||||
| Name | SEC inhibitor KL-1 | ||||||||||||
| CAS | 900308-84-1 | ||||||||||||
| Formula | C18H16ClNO4 | ||||||||||||
| Molar Mass | 345.78 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779. |
SEC inhibitor KL-1
CAS: 900308-84-1 F: C18H16ClNO4 W: 345.78
SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.